129747-52-0

Basic information

• Product Name: 5-Hydroxymethyl-nicotinic acid methyl ester
• Synonyms: 5-Hydroxymethyl-nicotinic acid methyl ester;Methyl (5-hydroxymethyl)nicotinate;5-(HydroxyMethyl)-3-pyridinecarboxylic Acid Methyl Ester;Methyl 5-(hydroxymethyl)
• CAS NO: 129747-52-0
• Molecular Formula: C₈H₉NO₃
• Molecular Weight: 167.17
• Mol File: 129747-52-0.mol

Chemical Properties

• Boiling Point: 316.3±32.0 °C(Predicted)
• Appearance: /
• Density: 1.244±0.06 g/cm3(Predicted)
• Storage Temp.: Inert atmosphere,Room Temperature
• PKA: 13.40±0.10(Predicted)
• CAS DataBase Reference: 5-Hydroxymethyl-nicotinic acid methyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 5-Hydroxymethyl-nicotinic acid methyl ester(129747-52-0)
• EPA Substance Registry System: 5-Hydroxymethyl-nicotinic acid methyl ester(129747-52-0)

Safety Data

• Hazardous Substances Data: 129747-52-0(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
5-Hydroxymethyl-nicotinic acid methyl ester is used as an intermediate in the synthesis of Nornicotine (N757000) analogs. These analogs are specifically designed to be used as haptens for immunoassays, which are essential tools in the detection and quantification of specific biomarkers, such as drugs, hormones, or other substances of interest. The compound's role in the synthesis of these analogs makes it a valuable component in the development of diagnostic tests and medical research.

Upstream product

• 179072-12-9 5-(tert-Butyl-diphenyl-silanyloxymethyl)-nicotinic acid 
• 67-56-1 methanol 
• 37669-64-0 (5-bromopyridin-3-yl)methanol 
• 201230-82-2 carbon monoxide 
• 1268245-99-3 C₁₃H₁₇NO₄ 
• 223563-60-8 C₁₁H₁₄BrNO₂ 
• 27828-71-3 5-hydroxynicotinic acid 
• 4591-55-3 dimethyl pyridine-3,5-dicarboxylate 
• 25761-06-2 5-methoxycarbonylpyrid-3-ylcarbonylchloride 
• 153607-77-3 3-Bromo-5-(tert-butyl-diphenyl-silanyloxymethyl)-pyridine 
• 179072-13-0 5-(tert-Butyl-diphenyl-silanyloxymethyl)-nicotinic acid methyl ester 

Downstream Products

• 878741-69-6 methyl 5-(cyanomethyl)pyridine-3-carboxylate 
• 562074-61-7 methyl 5-(chloromethyl)pyridine-3-carboxylate 
• 6221-06-3 methyl 5-formylpyridine-3-carboxylate 
• 179072-26-5 5-[2-(tert-Butyl-diphenyl-silanyloxy)-ethylsulfanylmethyl]-N,N-dimethyl-thionicotinamide 
• 179072-24-3 5-[2-(tert-Butyl-diphenyl-silanyloxy)-ethylsulfanylmethyl]-N,N-dimethyl-nicotinamide 
• 179072-25-4 5-[2-(tert-Butyl-diphenyl-silanyloxy)-ethylsulfanylmethyl]-N-methyl-thionicotinamide 
• 179072-16-3 5-[2-(tert-Butyl-diphenyl-silanyloxy)-ethylsulfanylmethyl]-nicotinic acid methyl ester 
• 179072-23-2 5-[2-(tert-Butyl-diphenyl-silanyloxy)-ethylsulfanylmethyl]-N-methyl-nicotinamide 
• 179072-18-5 5-[2-(tert-Butyl-diphenyl-silanyloxy)-ethylsulfanylmethyl]-thionicotinamide 
• 179072-17-4 5-[2-(tert-Butyl-diphenyl-silanyloxy)-ethylsulfanylmethyl]-nicotinamide 

Relevant articles and documents

HETEROCYCLIC FXR MODULATORS

The present technology is directed to compounds of formula (I), compositions, and methods related to modulation of FXR. In particular, the present compounds and compositions may be used to treat FXR-mediated disorders and conditions, including, e.g., liver disease, hyperlipidemia, hypercholesteremia, obesity, metabolic syndrome, cardiovascular disease, gastrointestinal disease, and atherosclerosis, and renal disease.

NOVEL FXR (NR1H4 ) BINDING AND ACTIVITY MODULATING COMPOUNDS

The present invention relates to compounds which bind to the NR1 H4 receptor (FXR) and act as agonists of the NR1 H4 receptor (FXR). The invention further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding of said nuclear receptor by said compounds, and to a process for the synthesis of said compounds.

Gonadotropin releasing hormone receptor antagonists

The present invention relates to Gonadotropin Releasing Hormone (“GnRH”) (also known as Leutinizing Hormone Releasing Hormone) receptor antagonists.

Synthesis biological and biological evaluation of some acyclic pyridine C-nucleosides. Part two

3-Bromo-5-(2-hydroxyethylthiomethyl)pyridine (7) was synthesized by reaction of 3-bromo-5-chloromethylpyridine hydrochloride (6) with the mono sodium salt of 2-mercaptoethanol. 3-Bromo-5-hydroxymethylpyridine (10) was, after protection as a silyl ether, c

Substituted alkylamine derivatives

The substituted alkylamine derivatives represented by formula (I) STR1 wherein R1 represents (a) substituted or unsubstituted C2-6 alkenyl group, (b) substituted or unsubstituted C3-6 cycloalkenyl group, (c) substituted or unsubstituted C2-6 alkynyl group, (d) substituted or unsubstituted aryl group, (e) substituted or unsubstituted heterocyclic group, (f) fused heterocyclic group which may be substituted, or (g) group represented by the formula Ru11 -Ar wherein R11 is a heterocyclic group and Ar is a 5- or 6-membered aromatic ring which may contain a hetero N, O or S atom, and which may be substituted; STR2 represents a 5- or 6-membered aromatic ring which may contain a hetero N, O or S atom, and may be substituted by R7, X and Y are linking groups, R2 is H or lower alkyl, R3 is hydrogen, lower alkyl, lower alkenyl, lower alkynyl or lower cycloalkyl, R4 and R5 are independently hydrogen or halogen atoms, R6 represents (a) substituted or unsubstituted acyclic hydrocarbon group which may be unsaturated, (b) substituted or unsubstituted cycloalkyl group, or (c) substituted or unsubstituted phenyl group, or non-toxic salts thereof. (E)-N-(6-6-dimethyl-2-hepten-4-ynyl)-N-ethyl-3-[4-(3-thienyl)-2-thienyl-methyloxy]benzylamine hydrochloride is a representative example. The substituted alkylamine derivatives are useful as pharmaceuticals, particularly for the treatment and prevention of hypercholesterolemia, hyperlipemia and arteriosclerosis.